The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 12)
Research Grant, 2017
The US Food and Drug (FDA) requires acceptable outcome measures to approve a cognitive-enhancing medication for the treatment of mild cognitive impairment (MCI) in Parkinson's disease (PD). The FDA has indicated that the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) is an acceptable combined cognitive-functional outcome for use in clinical trials; however, the CDR-SOB has ...
Researchers: Daniel Weintraub, MD
Improved Biomarkers and Clinical Outcome Measures, 2016
There is a great need to identify Parkinson's disease (PD) in its earliest stages when interventions may prevent or slow neural degeneration. Given that the earliest brain pathology of PD occurs outside of the motor system, namely in the olfactory bulbs (brain regions that detect smell) and the brainstem (brain region that controls involuntary functions), we are probing the functi...
Therapeutic Pipeline Program, 2014
By the time Parkinson's disease (PD) symptoms appear, typically 60% of neurons in the substantia nigra and their axonal projections (nerve fibers) to the striatum have degenerated. Since targeted axonal outgrowth is limited in the central nervous system, our approach is it to a use tissue engineering strategy to directly restore substantia nigra neurons and their...
Rapid Response Innovation Awards, 2013
In Parkinson's disease, the neocortex (outer layer of the brain's cerebral hemispheres, made of six layers) is less vulnerable than the allocortex (fewer than six layers) to alpha-synuclein pathology. No one knows the reason for this striking difference. However, we have found that the neocortex is more resistant to protein-misfolding stress (proteotoxicity) than a...
Researchers: Rehana K. Leak, PhD
RRIA (Rapid Response Innovation Awards), 2013
Recently it has been suggested that ingested environmental toxins may trigger a series of events, starting in the gastrointestinal tract, that eventually result in Parkinson's disease. Gastrointestinal dysfunctions have been recognized as occurring in many parkinsonian patients at early stages of the disease. The present project will test the hypothesis that lectin...
Researchers: Renato Alberto Travagli, PhD